Microbiotica raises £50 million ($67 million) to advance the pipeline of microbiome-based therapeutics, and receives Crohn’s and Colitis Foundation funding to develop the company’s bacterial therapeutic MB310 for the treatment of ulcerative colitis.
Careers | Find us | Contact us
Microbiotica raises £50 million ($67 million) to advance the pipeline of microbiome-based therapeutics, and receives Crohn’s and Colitis Foundation funding to develop the company’s bacterial therapeutic MB310 for the treatment of ulcerative colitis.
Wellcome Genome Campus,
Hinxton, Cambridgeshire,
CB10 1SA. UK
+44 (0)1223 834244


Wellcome Genome Campus,
Hinxton, Cambridgeshire, CB10 1SA. UK
+44 (0)1223 834244

